Althea adds new aseptic fill/finish line amid cost concerns

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/RGtimeline)
(Image: iStock/RGtimeline)
Ajinomoto Althea, Inc. has added a new aseptic fill/finish line in response to client's concerns regarding active pharmaceutical ingredient (API) manufacturing costs.

The San Diego, CA-based contract development and manufacturing organization (CDMO) installed the Optima VFVM 7000 aseptic fill/finish line.

"All of our clients are concerned with the cost of manufacturing API. The ability to maximize yield from the filling line was a key driver for this project​," Stacy Sutton, head of engineering at Althea told

"This line has the capability to use two different pumping systems, rotary piston and peristaltic. The ability to use single use disposable filling assemblies in conjunction with peristaltic pumps is a key feature​," she added.

The line also has features to minimize drug product loss, including start and end of production modes, Sutton explained.

Additionally, the new line enables larger batch sizes and a wider filling volume range (0.2 mL up to 100 mL). The equipment also provides 100% in-process-control and nitrogen purging.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more